Monday, February 22, 2010 (Last Updated: 02/24/2010)
MONDAY, Feb. 22 (HealthDay News) -- Serum cell-free DNA (cf-DNA) integrity may serve as a predictive marker for the diagnosis and detection of clear renal cell carcinoma (cRCC), according to a study in the February issue of Urology.
Noting that larger DNA fragments present in serum come from necrotic cells such as cancer cells rather than normal cells undergoing apoptosis, Feng Gang, M.D., and colleagues from University Jean-Monnet in St-Etienne, France, examined cf-DNA integrity in the serum of 78 patients with cRCC before surgery and in 42 patients without cancer.
Using the polymerase chain reaction to amplify products of various sizes from a housekeeping gene, the researchers found that cf-DNA integrity was significantly higher in the serum of cancer patients compared with controls. In addition, cf-DNA integrity was significantly different pre-operation as compared to post-operation in 22 cancer patients whose blood was collected before and after surgery.
"Our results indicated that serum cf-DNA integrity in patients with cRCC was significantly increased as compared with that in controls without tumor," the authors write. "Thus, serum cf-DNA integrity may be a potential tool for the detection and diagnosis of cRCC."
Copyright © 2010 HealthDay. All rights reserved.